U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07773987) titled 'Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction and Unmasking of Tumor Antigenicity in the Microenvironment for Head and Neck Cancer' on Aug. 12.
Brief Summary: This is a non-comparative randomized Phase 2 study using the INITIUM regimen with or without elective nodal irradiation (ENI) delivered before surgery for resectable head and neck squamous cell carcinoma (HNSCC).
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Head and Neck Cancer Squamous Cell Carcinoma
Intervention:
DRUG: Pembrolizumab
All patients will undergo induction with pembrolizumab (200 mg) given intravenously every three ...